U.K. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Physiomics

Market Cap: UK£1.3m

Provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland.

N4 Pharma

Market Cap: UK£3.1m

A specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom.

Cizzle Biotechnology Holdings

Market Cap: UK£6.1m

Develops an immunoassay test for the CIZ1B, a non-invasive diagnostic tool for the early detection of lung cancer in the United Kingdom.

Poolbeg Pharma

Market Cap: UK£22.7m

A clinical-stage biopharmaceutical company, focused on acquiring, developing, and commercialising of medicines for unmet medical needs in the United Kingdom.

IXICO

Market Cap: UK£9.4m

Provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States.

Animalcare Group

Market Cap: UK£202.8m

Develops, sells, and distributes licensed veterinary pharmaceuticals, and services for companion and production animals, and equine veterinary markets.

Oxford Nanopore Technologies

Market Cap: UK£1.4b

Engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA.

hVIVO

Market Cap: UK£73.1m

Operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America.

ECO Animal Health Group

Market Cap: UK£40.7m

Develops, registers, and markets pharmaceutical products for animals worldwide.

4basebio

Market Cap: UK£152.5m

Engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and non-viral vector solutions in Europe, the United States, and internationally.

Futura Medical

Market Cap: UK£22.6m

Research, develops, and sells pharmaceutical and healthcare products for sexual health.

genedrive

Market Cap: UK£9.1m

Engages in the design, development, and manufacture of molecular diagnostics testing equipment for use in genotyping, pathogen detection, infectious disease detection, and other clinical indications.

Bioventix

Market Cap: UK£143.7m

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

OptiBiotix Health

Market Cap: UK£11.6m

A life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally.

Sareum Holdings

Market Cap: UK£26.5m

A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.

ProBiotix Health

Market Cap: UK£10.3m

Develops probiotics to tackle cardiovascular disease and other lifestyle conditions in the United Kingdom, the United States, and internationally.

SkinBioTherapeutics

Market Cap: UK£42.7m

A life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally.

Theracryf

Market Cap: UK£5.4m

A clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioural brain disorders.

Ovoca Bio

Market Cap: UK£938.0k

A clinical-stage biopharmaceutical company, develops and commercializes novel product candidates for women health.

Diaceutics

Market Cap: UK£98.5m

A diagnostic commercialization company, provides data, data analytics, and implementation services for pharma and biotech companies.

Nuformix

Market Cap: UK£1.7m

Together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom.

Oxford BioDynamics

Market Cap: UK£5.9m

Operates as a biotechnology company that discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom.

Fusion Antibodies

Market Cap: UK£7.3m

A contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally.

Oxford Biomedica

Market Cap: UK£352.9m

A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.

Verici Dx

Market Cap: UK£2.7m

Develops prognostic and diagnostic tests for kidney transplant patients.

Hikma Pharmaceuticals

Market Cap: UK£4.4b

Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.

Arecor Therapeutics

Market Cap: UK£16.4m

A clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom.

BSF Enterprise

Market Cap: UK£2.3m

Develops and commercializes cutting-edge tissue-engineered solutions.

Aptamer Group

Market Cap: UK£7.6m

Provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally.

Roquefort Therapeutics

Market Cap: UK£2.0m

A material biotech company, engages in the development of medicines for the treatment of cancer.

Incanthera

Market Cap: UK£5.8m

A dermatology and oncology therapeutics company, focuses on the dermatological formulation and delivery technologies for various indications.

ValiRx

Market Cap: UK£2.2m

A biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.

Kanabo Group

Market Cap: UK£1.4m

A digital health company, engages in the research, development and commercialization of cannabis-derived formulations and therapeutic inhalation devices.

Hemogenyx Pharmaceuticals

Market Cap: UK£7.0m

A clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer.